This study investigates advanced pancreatic cancer. It looks at how well Trilaciclib combined with mFOLFIRINOX works for people who have this condition.
The study evaluates the safety and effects of the treatment, particularly focusing on reducing side effects related to chemotherapy.
- Who can participate: Adults aged 18 to 75 with confirmed pancreatic cancer who have not had previous cancer treatment can participate. They must meet specific health criteria and agree to use birth control if of reproductive age.
- Study details: Participants will receive a combination of Trilaciclib and mFOLFIRINOX. The study will monitor safety and side effects.